테네시의 삼중음성 유방암 임상 시험
삼중음성 유방암 관련 연구 31개가 테네시 내 여러 지역에서 참여자를 모집하고 있습니다.
테네시의 도시
공식 연구 텍스트(영어)
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Tennessee Oncology, Nashville
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT06270706A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology PLLC, Nashville
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT06465069The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Sarah Cannon Research Institute, Nashville
피험자 모집 중1/2상
12세 이상 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT04585750A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Sarah Cannon Research Institute (SCRI), Nashville
피험자 모집 중1상
19세 이상 · 모든 성별 · 2026. 10. 1. 업데이트됨 · NCT06586957Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 30. 업데이트됨 · NCT05422794First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
- SCRI Oncology Partners, Nashville
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 29. 업데이트됨 · NCT06799065Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Vanderbilt University Medical Center, Nashville
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT04981119A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- SCRI Oncology Partners ( Site 7004), Nashville
- Tennessee Oncology ( Site 0018), Nashville
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06841354Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- West Cancer Center and Research Institute ( Site 0084), Germantown
- Baptist Cancer Center ( Site 0101), Memphis
- One Oncology - Tennessee Oncology ( Site 0098), Nashville
- 외 3개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06393374A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Tennessee Cancer Specialists ( Site 7001), Knoxville
- SCRI Oncology Partners ( Site 7005), Nashville
- Nashville General Hospital ( Site 0017), Nashville
- 외 1개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06966700A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- University of Tennessee Medical Center, Knoxville
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 23. 업데이트됨 · NCT06618287Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Sarah Cannon - Tennessee Oncology, Nashville
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 21. 업데이트됨 · NCT05983432Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
- Sarah Cannon Research Institute, Nashville
피험자 모집 중1상
18세 이상 · 여성 · 2026. 9. 10. 업데이트됨 · NCT07652242Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- University of Tennessee, Knoxville
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 9. 업데이트됨 · NCT05633654Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Nashville General, Nashville
피험자 모집 중관찰 연구
18세 ~ 99세 · 모든 성별 · 2026. 9. 3. 업데이트됨 · NCT07211178A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Nashville
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 8. 18. 업데이트됨 · NCT07182149A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Vanderbilt University Medical Center, Nashville
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 8. 17. 업데이트됨 · NCT04895709SMP-3124LP in Adults With Advanced Solid Tumors
- SCRI Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 8. 12. 업데이트됨 · NCT06526819Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Sarah Cannon Research Institute at Tennessee Oncology, Nashville
- Tennessee Oncology, Nashville
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 8. 4. 업데이트됨 · NCT05579366A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- Tennessee Oncology, Nashville
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 7. 28. 업데이트됨 · NCT06150664A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Sarah Cannon Research Institute (SCRI), Nashville
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 6. 29. 업데이트됨 · NCT05377996Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy
- Vanderbilt University/Ingram Cancer Center, Nashville
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 6. 24. 업데이트됨 · NCT05770531A Study of LY4175408 in Participants With Advanced Cancer
- Sarah Cannon Research Institute, Nashville
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 6. 23. 업데이트됨 · NCT07046923Study of XB010 in Subjects With Solid Tumors
- SCRI Oncology Partners, Nashville
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 6. 22. 업데이트됨 · NCT06545331A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- SCRI Oncology Partners, Nashville
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 6. 18. 업데이트됨 · NCT07503808Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
- Vanderbilt-Ingram Cancer Center, Nashville
피험자 모집 중
18세 이상 · 모든 성별 · 2026. 5. 6. 업데이트됨 · NCT07555210Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
- Vanderbilt-Ingram Cancer Center, Nashville
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 5. 4. 업데이트됨 · NCT04434040Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
- Sarah Cannon Research Institute, Chattanooga
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 4. 29. 업데이트됨 · NCT04468061A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
- West Cancer Centre, Germantown
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, PLLC, Nashville
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 1. 30. 업데이트됨 · NCT06926920Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
- Vanderbilt University/Ingram Cancer Center, Nashville
피험자 모집 중2상
18세 이상 · 모든 성별 · 2025. 10. 30. 업데이트됨 · NCT07016399A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
- SCRI Oncology Partners, Nashville
피험자 모집 중2상
18세 이상 · 모든 성별 · 2025. 6. 19. 업데이트됨 · NCT06568692ClinicalTrials.gov 출처, 2026. 10. 6. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.